Hematology

In the evolving landscape of haematologic cancers, the concept of minimal residual disease, also known as measurable residual disease…

A groundbreaking study has introduced a novel, image-based blood test that could significantly enhance the way doctors manage and personalise treatment for coronary artery disease (CAD), a leading global cause of death.

A novel form of CAR T-cell therapy, engineered to enhance immune response, is showing encouraging results in patients with relapsed or refractory lymphoma who previously failed anti-CD19 CAR T-cell treatment.

A recent study has found that women with sickle cell disease experience higher inflammation during the follicular phase of their menstrual cycle, which may explain the timing of pain episodes and offer insight into more personalised care.

A retrospective analysis of global data has found that a specific treatment sequence, starting with small molecule inhibitors and followed by epigenetic modifiers, may significantly improve survival in patients with relapsed or refractory T-cell lymphomas.

A newly recognised subtype of Castleman disease (CD), termed oligocentric CD (OligoCD), has been identified and characterised through the ACCELERATE natural history registry….

A new study from the COMBI-AD trial shows that circulating tumour DNA (ctDNA) testing can accurately predict recurrence and survival in stage III melanoma, offering a potential tool for personalising treatment.